{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:34:32Z","timestamp":1793604872070,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02220-z","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:34:43Z","timestamp":1741152883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Race, Genetics, and Social Determinants of Health in Transthyretin Cardiac Amyloidosis: A Literature Review and Call to Action"],"prefix":"10.1007","volume":"27","author":[{"given":"Gracia","family":"Fahed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana N.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nixuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Isaiah","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kitakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus E.","family":"Pino Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2220_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet"},{"key":"2220_CR2","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC202303210","volume":"176","author":"MW Bloom","year":"2023","unstructured":"Bloom MW, Gorevic PD. Cardiac amyloidosis. Ann Intern Med. 2023;176:ITC33\u201348.","journal-title":"Ann Intern Med"},{"key":"2220_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: A systematic review. JAMA. 2020;324:79\u201389.","journal-title":"JAMA"},{"key":"2220_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","volume":"3","author":"KM Alexander","year":"2018","unstructured":"Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis. JAMA Cardiol. 2018;3:865.","journal-title":"JAMA Cardiol"},{"key":"2220_CR5","doi-asserted-by":"crossref","unstructured":"Fahed G, Jimenez JI, Cai N, Xiaokang W, Edmonds A, Shah K et al. Socioeconomic and Geographic Disparities in the Reported US Amyloidosis Mortality from 2018\u20132022: A Persistent Underdetection? JACC Heart Fail. 2025; in press.","DOI":"10.1016\/j.jchf.2024.11.021"},{"key":"2220_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.122.060042","volume":"146","author":"DM Kimenai","year":"2022","unstructured":"Kimenai DM, Pirondini L, Gregson J, Prieto D, Pocock SJ, Perel P, et al. Socioeconomic deprivation: an important, largely unrecognized risk factor in primary prevention of cardiovascular disease. Circulation. 2022;146:240\u20138.","journal-title":"Circulation"},{"key":"2220_CR7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.117.029652","volume":"137","author":"WM Schultz","year":"2018","unstructured":"Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 2018;137:2166\u201378.","journal-title":"Circulation"},{"key":"2220_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","volume":"130","author":"TM Powell-Wiley","year":"2022","unstructured":"Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, et al. Social determinants of cardiovascular disease. Circ Res. 2022;130:782\u201399.","journal-title":"Circ Res"},{"key":"2220_CR9","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 [cited 2023 Dec 26];145. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"2220_CR10","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K et al. HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America. J Card Fail. 2024;S1071-9164(24)00232-X.","DOI":"10.1016\/j.cardfail.2024.07.001"},{"key":"2220_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/eurheartj\/ehs070","volume":"33","author":"JE Ho","year":"2012","unstructured":"Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012;33:1734\u201341.","journal-title":"Eur Heart J"},{"key":"2220_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/eurheartj\/ehaa071","volume":"41","author":"J Motiej\u016bnait\u0117","year":"2020","unstructured":"Motiej\u016bnait\u0117 J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi D-J, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart J. 2020;41:1357\u201364.","journal-title":"Eur Heart J"},{"key":"2220_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1089\/jwh.2012.4107","volume":"22","author":"DE Feldman","year":"2013","unstructured":"Feldman DE, Huynh T, Des Lauriers J, Giannetti N, Frenette M, Grondin F, et al. Gender and other disparities in referral to specialized heart failure clinics following emergency department visits. J Womens Health (Larchmt). 2013;22:526\u201331.","journal-title":"J Womens Health (Larchmt)"},{"key":"2220_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jchf.2018.11.005","volume":"7","author":"P Dewan","year":"2019","unstructured":"Dewan P, R\u00f8rth R, Jhund PS, Ferreira JP, Zannad F, Shen L, et al. Income inequality and outcomes in heart failure: A global Between-Country analysis. JACC Heart Fail. 2019;7:336\u201346.","journal-title":"JACC Heart Fail"},{"key":"2220_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jchf.2019.01.008","volume":"7","author":"EM DeFilippis","year":"2019","unstructured":"DeFilippis EM, Truby LK, Garan AR, Givens RC, Takeda K, Takayama H, et al. Sex-Related differences in use and outcomes of left ventricular assist devices as Bridge to transplantation. JACC Heart Fail. 2019;7:250\u20137.","journal-title":"JACC Heart Fail"},{"key":"2220_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/CIRCULATIONAHA.118.037369","volume":"139","author":"EM Hsich","year":"2019","unstructured":"Hsich EM. Sex differences in advanced heart failure therapies. Circulation. 2019;139:1080\u201393.","journal-title":"Circulation"},{"key":"2220_CR17","doi-asserted-by":"publisher","first-page":"e003552","DOI":"10.1161\/CIRCOUTCOMES.116.003552","volume":"10","author":"B Ziaeian","year":"2017","unstructured":"Ziaeian B, Kominski GF, Ong MK, Mays VM, Brook RH, Fonarow GC. National differences in trends for heart failure hospitalizations by sex and race\/ethnicity. Circ Cardiovasc Qual Outcomes. 2017;10:e003552.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2220_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.168.19.2138","volume":"168","author":"H Bahrami","year":"2008","unstructured":"Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168:2138\u201345.","journal-title":"Arch Intern Med"},{"key":"2220_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.healun.2016.01.1231","volume":"35","author":"AA Morris","year":"2016","unstructured":"Morris AA, Kransdorf EP, Coleman BL, Colvin M. Racial and ethnic disparities in outcomes after heart transplantation: A systematic review of contributing factors and future directions to close the outcomes gap. J Heart Lung Transpl. 2016;35:953\u201361.","journal-title":"J Heart Lung Transpl"},{"key":"2220_CR20","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.jacc.2019.02.042","volume":"73","author":"P Glynn","year":"2019","unstructured":"Glynn P, Lloyd-Jones DM, Feinstein MJ, Carnethon M, Khan SS. Disparities in cardiovascular mortality related to heart failure in the united States. J Am Coll Cardiol. 2019;73:2354\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"2220_CR21","doi-asserted-by":"publisher","first-page":"e004173","DOI":"10.1161\/CIRCHEARTFAILURE.117.004173","volume":"11","author":"B Wayda","year":"2018","unstructured":"Wayda B, Clemons A, Givens RC, Takeda K, Takayama H, Latif F, et al. Socioeconomic disparities in adherence and outcomes after heart transplant: A UNOS (United network for organ Sharing) registry analysis. Circ Heart Fail. 2018;11:e004173.","journal-title":"Circ Heart Fail"},{"key":"2220_CR22","doi-asserted-by":"publisher","first-page":"e007264","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","volume":"13","author":"A Nayak","year":"2020","unstructured":"Nayak A, Hicks AJ, Morris AA. Understanding the complexity of heart failure risk and treatment in black patients. Circ Heart Fail. 2020;13:e007264.","journal-title":"Circ Heart Fail"},{"key":"2220_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJM199511023331806","volume":"333","author":"MW Rich","year":"1995","unstructured":"Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190\u20135.","journal-title":"N Engl J Med"},{"key":"2220_CR24","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.jacc.2018.02.077","volume":"71","author":"TP Baggett","year":"2018","unstructured":"Baggett TP, Liauw SS, Hwang SW. Cardiovascular disease and homelessness. J Am Coll Cardiol. 2018;71:2585\u201397.","journal-title":"J Am Coll Cardiol"},{"key":"2220_CR25","doi-asserted-by":"publisher","first-page":"e004052","DOI":"10.1161\/CIRCOUTCOMES.117.004052","volume":"11","author":"EA Akwo","year":"2018","unstructured":"Akwo EA, Kabagambe EK, Harrell FE, Blot WJ, Bachmann JM, Wang TJ, et al. Neighborhood deprivation predicts heart failure risk in a Low-Income population of Blacks and Whites in the southeastern united States. Circ Cardiovasc Qual Outcomes. 2018;11:e004052.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2220_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCOUTCOMES.113.000911","volume":"7","author":"B Bikdeli","year":"2014","unstructured":"Bikdeli B, Wayda B, Bao H, Ross JS, Xu X, Chaudhry SI, et al. Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. Circ Cardiovasc Qual Outcomes. 2014;7:749\u201356.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2220_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.cardfail.2020.07.014","volume":"26","author":"GH Bevan","year":"2020","unstructured":"Bevan GH, Josephson R, Al-Kindi SG. Socioeconomic deprivation and heart failure mortality in the united States. J Card Fail. 2020;26:1106\u20137.","journal-title":"J Card Fail"},{"key":"2220_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ejheart.2006.02.008","volume":"8","author":"S Stewart","year":"2006","unstructured":"Stewart S, Murphy NF, McMurray JJV, Jhund P, Hart CL, Hole D. Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: an analysis of the Renfrew\/Paisley study. Eur J Heart Fail. 2006;8:856\u201363.","journal-title":"Eur J Heart Fail"},{"key":"2220_CR29","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;73:2872\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"2220_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","volume":"26","author":"M Bruno","year":"2021","unstructured":"Bruno M, Casta\u00f1o A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26:35\u201345.","journal-title":"Heart Fail Rev"},{"key":"2220_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cardfail.2020.08.007","volume":"27","author":"J Batra","year":"2021","unstructured":"Batra J, Rosenblum H, Defilippis EM, Griffin JM, Saith SE, Gamino D, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutation: insights from noninvasive Pressure-Volume analysis. J Card Fail. 2021;27:67\u201374.","journal-title":"J Card Fail"},{"key":"2220_CR32","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis. Eur J Heart Fail. 2022;24:2355\u201363.","journal-title":"Eur J Heart Fail"},{"key":"2220_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","volume":"29","author":"A Aimo","year":"2023","unstructured":"Aimo A, Panichella G, Garofalo M, Gasparini S, Arzilli C, Castiglione V, et al. Sex differences in transthyretin cardiac amyloidosis. Heart Fail Rev. 2023;29:321\u201330.","journal-title":"Heart Fail Rev"},{"key":"2220_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s44263-023-00016-3","volume":"1","author":"EC Madu","year":"2023","unstructured":"Madu EC, Mezue K. Uneven burden of cardiac amyloidosis in people of African descent \u2014 global imbalance in resources and access. BMC Global Public Health. 2023;1:15.","journal-title":"BMC Global Public Health"},{"key":"2220_CR35","unstructured":"National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Health and Medicine Division; Committee on Population; Board on Health Sciences Policy; Committee on the Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field [Internet]. Washington (DC): National Academies Press (US); 2023 [cited 2025 Feb 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589855\/"},{"key":"2220_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cardfail.2024.08.055","volume":"31","author":"JA Regan","year":"2025","unstructured":"Regan JA, Khouri MG, Olabisi OA, Alexander KM, Khan SS, Shah SH, et al. Should we systematically screen for the amyloidogenic V142I variant?? J Card Fail. 2025;31:136\u20139.","journal-title":"J Card Fail"},{"key":"2220_CR37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: A review. JAMA. 2024;331:778.","journal-title":"JAMA"},{"key":"2220_CR38","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","volume":"322","author":"SM Damrauer","year":"2019","unstructured":"Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry. JAMA. 2019;322:2191\u2013202.","journal-title":"JAMA"},{"key":"2220_CR39","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","volume":"327","author":"V Parcha","year":"2022","unstructured":"Parcha V, Malla G, Irvin MR, Armstrong ND, Judd SE, Lange LA, et al. Association of transthyretin Val122Ile variant with incident heart failure among black individuals. JAMA. 2022;327:1368\u201378.","journal-title":"JAMA"},{"key":"2220_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372:21\u20139.","journal-title":"N Engl J Med"},{"key":"2220_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchf.2021.09.006","volume":"10","author":"AC Coniglio","year":"2022","unstructured":"Coniglio AC, Segar MW, Loungani RS, Savla JJ, Grodin JL, Fox ER, et al. Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail. 2022;10:129\u201338.","journal-title":"JACC Heart Fail"},{"key":"2220_CR42","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","volume":"331","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, et al. Cardiovascular burden of the V142I transthyretin variant. JAMA. 2024;331:1824\u201333.","journal-title":"JAMA"},{"key":"2220_CR43","doi-asserted-by":"publisher","first-page":"e003356","DOI":"10.1161\/CIRCGEN.121.003356","volume":"14","author":"P Chandrashekar","year":"2021","unstructured":"Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, et al. Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: A systematic review. Circ Genom Precis Med. 2021;14:e003356.","journal-title":"Circ Genom Precis Med"},{"key":"2220_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","volume":"10","author":"T Martyn","year":"2022","unstructured":"Martyn T, Saef J, Dey AR, Khedraki R, Jain V, Collier P, et al. Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function. JACC Heart Fail. 2022;10:689\u201391.","journal-title":"JACC Heart Fail"},{"key":"2220_CR45","doi-asserted-by":"crossref","unstructured":"Fahed G, Jimenez JI, Fronseca MIA, Hu J, Spencer-Bonilla G, Haddad F et al. The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis. JACC Heart Fail. 2025; in press.","DOI":"10.1016\/j.jchf.2024.11.022"},{"key":"2220_CR46","doi-asserted-by":"publisher","unstructured":"Aggarwal V, Mohanty A, Seltzer R, Ghannam H, Dev S. Abstract 12799: Geographic Variation in Cardiac Amyloidosis in U.S. Veterans From 2012 to 2021. Circulation [Internet]. 2023 [cited 2024 Dec 11];148. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/circ.148.suppl_1.12799","DOI":"10.1161\/circ.148.suppl_1.12799"},{"key":"2220_CR47","first-page":"454","volume":"6","author":"B Shankar","year":"2024","unstructured":"Shankar B, Yanek L, Jefferson A, Jani V, Brown E, Tsottles D, et al. Race and socioeconomic status impact diagnosis and clinical outcomes in transthyretin cardiac amyloidosis. JACC: CardioOncology. 2024;6:454\u201363.","journal-title":"JACC: CardioOncology"},{"key":"2220_CR48","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267\u201374.","journal-title":"JAMA Cardiol"},{"key":"2220_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): A targeted literature review. Cardiol Ther. 2021;10:141\u201359.","journal-title":"Cardiol Ther"},{"key":"2220_CR50","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Writing Committee, Kittleson","year":"2023","unstructured":"Writing Committee, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81:1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"key":"2220_CR51","doi-asserted-by":"publisher","unstructured":"Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV et al. Transthyretin Cardiac Amyloidosis in Black Americans. Circ: Heart Failure [Internet]. 2016 [cited 2024 Dec 11];9. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002558","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558"},{"key":"2220_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2021.11.048","volume":"167","author":"JM Bourque","year":"2022","unstructured":"Bourque JM, Schepart A, Bhambri R, Casta\u00f1o A, O\u2019Brien A, Chen Y, et al. Temporal trends in diagnostic testing patterns for Wild-Type transthyretin amyloid cardiomyopathy in the medicare Fee-for-Service population. Am J Cardiol. 2022;167:98\u2013103.","journal-title":"Am J Cardiol"},{"key":"2220_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cardfail.2023.09.016","volume":"30","author":"LK Stern","year":"2024","unstructured":"Stern LK, Grodin JL, Maurer MS, Ruberg FL, Patel AR, Khouri MG, et al. The cardiac amyloidosis registry study (CARS): rationale, design and methodology. J Card Fail. 2024;30:669\u201378.","journal-title":"J Card Fail"},{"key":"2220_CR54","unstructured":"Lexi-Drugs. [Internet]. UpToDate Lexidrug. [cited 2025 Jan 10]. Available from: https:\/\/online.lexi.com"},{"key":"2220_CR55","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","volume":"5","author":"A Masri","year":"2020","unstructured":"Masri A, Chen H, Wong C, Fischer KL, Karam C, Gellad WF, et al. Initial experience prescribing commercial Tafamidis, the most expensive cardiac medication in history. JAMA Cardiol. 2020;5:1066\u20137.","journal-title":"JAMA Cardiol"},{"key":"2220_CR56","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81:1835\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"2220_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","volume":"15","author":"G Spencer-Bonilla","year":"2021","unstructured":"Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM. Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep. 2021;15:8.","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2220_CR58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/HCO.0000000000000849","volume":"36","author":"TU Azam","year":"2021","unstructured":"Azam TU, Colvin MM. Representation of black patients in heart failure clinical trials. Curr Opin Cardiol. 2021;36:329\u201334.","journal-title":"Curr Opin Cardiol"},{"key":"2220_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1\u20139.","journal-title":"Amyloid"},{"key":"2220_CR60","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132\u201342.","journal-title":"N Engl J Med"},{"key":"2220_CR61","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med"},{"key":"2220_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","volume":"30","author":"AA Girard","year":"2025","unstructured":"Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev. 2025;30:69\u201373.","journal-title":"Heart Fail Rev"},{"key":"2220_CR63","doi-asserted-by":"publisher","first-page":"e2442204","DOI":"10.1001\/jamanetworkopen.2024.42204","volume":"7","author":"DA Taira","year":"2024","unstructured":"Taira DA, Ranken MS, Seto BK, Davis J, Hermosura AH, Porter C, et al. Representation of native Hawaiian and Pacific Islander individuals in clinical trials. JAMA Netw Open. 2024;7:e2442204.","journal-title":"JAMA Netw Open"},{"key":"2220_CR64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s43856-024-00586-9","volume":"4","author":"JY Kim","year":"2024","unstructured":"Kim JY, Florez M, Botto E, Belgrave X, Grace C, Getz K. The influence of socioeconomic status on individual attitudes and experience with clinical trials. Commun Med (Lond). 2024;4:172.","journal-title":"Commun Med (Lond)"},{"key":"2220_CR65","doi-asserted-by":"publisher","first-page":"e020466","DOI":"10.1161\/JAHA.120.020466","volume":"10","author":"AE Johnson","year":"2021","unstructured":"Johnson AE, Zhu J, Garrard W, Thoma FW, Mulukutla S, Kershaw KN, et al. Area deprivation index and cardiac readmissions: evaluating Risk-Prediction in an electronic health record. J Am Heart Assoc. 2021;10:e020466.","journal-title":"J Am Heart Assoc"},{"key":"2220_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/jamiaopen\/ooz024","volume":"2","author":"DM Zulman","year":"2019","unstructured":"Zulman DM, Wong EP, Slightam C, Gregory A, Jacobs JC, Kimerling R, et al. Making connections: nationwide implementation of video telehealth tablets to address access barriers in veterans. JAMIA Open. 2019;2:323\u20139.","journal-title":"JAMIA Open"},{"key":"2220_CR67","unstructured":"Amyloidosis Research Consortium [Internet]. [cited 2025 Jan 10]. Available from: https:\/\/arci.org."},{"key":"2220_CR68","unstructured":"Amyloidosis Foundation [Internet]. [cited 2025 Jan 10]. Available from: https:\/\/www.amyloidosis.org"},{"key":"2220_CR69","unstructured":"Amyloidosis Support Groups Inc. [Internet]. [cited 2025 Jan 10]. Available from: https:\/\/www.amyloidosissupport.org"},{"key":"2220_CR70","doi-asserted-by":"crossref","unstructured":"Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine OF et al. Artificial Intelligence\u2013Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clinic Proceedings. 2021;96:2768\u201378.","DOI":"10.1016\/j.mayocp.2021.04.023"},{"key":"2220_CR71","doi-asserted-by":"publisher","first-page":"e002884","DOI":"10.1136\/openhrt-2024-002884","volume":"11","author":"RS-W Chang","year":"2024","unstructured":"Chang RS-W, Chiu I-M, Tacon P, Abiragi M, Cao L, Hong G, et al. Detection of cardiac amyloidosis using machine learning on routine echocardiographic measurements. Open Heart. 2024;11:e002884.","journal-title":"Open Heart"},{"key":"2220_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","volume":"5","author":"JH Gurwitz","year":"2020","unstructured":"Gurwitz JH, Maurer MS. Tafamidis-A pricey therapy for a Not-So-Rare condition. JAMA Cardiol. 2020;5:247\u20138.","journal-title":"JAMA Cardiol"},{"key":"2220_CR73","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/ajhp\/zxae183","volume":"81","author":"KM Walenczyk","year":"2024","unstructured":"Walenczyk KM, Singh A, Tong K, Burg MM, Miller EJ. From transthyretin cardiac amyloidosis diagnosis to Tafamidis treatment: association of drop-off with patient sociodemographic characteristics. Am J Health Syst Pharm. 2024;81:1245\u201351.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02220-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:03:41Z","timestamp":1772096621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02220-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02220-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"19 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"66"}}